Language as a Regulated Asset: A Strategic Guide to MDR and IVDR Compliance for Quality and Compliance Teams

When the EU's Medical Device Regulation (MDR 2017/745) and In Vitro Diagnostic Regulation (IVDR 2017/746) came into force, the compliance conversation in most organizations defaulted to the familiar: technical files, notified body timelines, EUDAMED registration, SSCP authoring. What didn't make it to the top of many compliance agendas early enough — and still doesn't in too many organizations — was language.

That is a strategic miscalculation. And for quality and compliance teams who are accountable for EU market readiness, it is one worth correcting before the consequences become visible in a regulatory submission, a Competent Authority review, or a delayed product launch.

This post is for the teams who own that accountability. It is not an overview of MDR and IVDR — you know the regulations. It is a deeper look at where language risk lives inside your compliance program, how technology is reshaping what's possible, and what a mature language strategy actually looks like in practice.

The Philosophical Shift MDR and IVDR Actually Made

The transition from MDD/IVDD to MDR/IVDR is often described in terms of documentation burden — more requirements, more scrutiny, more volume. That framing is accurate but incomplete.

What the new regulations actually did was change the underlying model. MDD and IVDD were built around pre-market approval as the primary compliance gate. Once a device cleared that gate, the obligations were largely static. MDR and IVDR replaced that model with full lifecycle accountability — a continuous loop of post-market surveillance, clinical evaluation updates, PSUR reporting, and public transparency. That shift has direct consequences for language management that are still not fully understood across the industry.

Under a pre-market model, translation was a project: you translated your IFU, your labeling, your technical documentation, and you were done until the next major revision. Under a lifecycle model, documentation is never static. Clinical evaluations are updated. PMS plans evolve. PSURs are filed on schedule. SSCPs and SSPs require ongoing maintenance and notified body revalidation. Every update cycle is a potential translation trigger — and if your language workflows aren't structured to absorb that rhythm, the backlog accumulates quickly.

Quality and compliance teams who treat language as a project instead of a process are managing a structural mismatch. The regulation expects continuous language governance. Many organizations are still delivering one-off translation briefs.

Where Language Risk Actually Sits

For compliance professionals, risk tends to be mapped to documentation gaps, notified body findings, or post-market incidents. Language risk is real and specific, but it can be harder to locate until it surfaces in a review. Here is where it typically lives.

Labeling and IFU inconsistency across markets. When translations are commissioned at different times through different processes, terminology diverges. A term that is consistently rendered in one national language may be translated differently in another, or differently across two revision cycles of the same document. This inconsistency creates exposure during market surveillance audits and, more importantly, creates genuine patient safety risk when instructions are unclear or contradictory.

EUDAMED language obligations. EUDAMED is not simply a registration database — it is a public transparency mechanism, and the language requirements around what must be published, in which languages, and at what level of readability are still being interpreted inconsistently across Member States. Manufacturers who have not mapped their EUDAMED obligations to their language program risk publishing documentation that does not meet Competent Authority expectations.

Supply chain fragmentation. Under MDR and IVDR, Authorized Representatives, importers, and distributors have explicit obligations to verify national language compliance. When economic operators are commissioning or modifying translations independently — without access to controlled glossaries or current source documentation — terminology diverges across the supply chain. That divergence becomes a finding in audits and a genuine risk during field safety events, when consistent communication across markets is critical.

Version control failures under update pressure. The PSUR cycle for Class IIb and Class III devices is annual. Every PSUR cycle may trigger updates to clinical evaluation reports, SSCP documents, and labeling. Without document version control that is explicitly integrated with translation workflows, it is easy for translated versions to fall behind their source counterparts — sometimes by more than one revision cycle.

The AI Question Quality Teams Need to Ask

Artificial intelligence is now actively reshaping the translation industry, and no compliance professional responsible for language can afford to ignore it. The more important question is not whether to use AI in translation workflows. It is which AI-enabled workflows are appropriate for regulated content, and what governance structures make them safe.

This is a distinction that matters, and it is one that separates responsible integration from wishful thinking.

Where AI creates genuine value in MDR/IVDR language workflows:

Large language models and AI-assisted translation engines have become genuinely capable of producing high-quality first drafts across a wide range of document types. For high-volume, repetitive content such as labeling updates, standard IFU sections, or boilerplate PSUR language, AI-assisted workflows can significantly reduce turnaround times and cost while maintaining consistency — provided they are operating within a controlled terminology framework.

The efficiency gains are real. A manufacturer maintaining translations across 10–15 EU languages for a portfolio of Class II and Class III devices is managing a considerable volume of content across multiple update cycles per year. AI-assisted workflows, when properly governed, can absorb that volume without proportionally increasing cost or turnaround time.

Where human expertise remains non-negotiable:

Safety-critical language is not a suitable context for unreviewed AI output. Instruction steps, contraindications, warnings, dosage information, and any language where misinterpretation creates patient harm risk require expert human review against controlled terminology standards — regardless of how capable the AI first draft is.

SSCP and SSP lay-language sections present a specific challenge. AI can produce readable text, but readability and regulatory appropriateness are not identical. A lay-language section that is fluent but that inadvertently promotes the device, overstates performance, or uses technically imprecise language will fail notified body validation. That review requires a human expert who understands both health literacy principles and the regulatory context of the document.

UDI verification, legal entity names, contraindication flags, and numerically critical content (dosages, dimensions, tolerances) must be verified by human review at every step. AI models do not hallucinate dramatically — but they do produce errors in precisely the areas where errors are most dangerous: specific numbers, specific terms, specific conditions.

The governance question:

At Language Intelligence, we integrate AI-assisted translation within human-governed workflows specifically designed for life sciences content. Our approach is not to replace expert judgment — it is to apply AI where it creates efficiency within a framework where subject matter experts retain control. Glossaries are locked. Every project operates against controlled terminology. Safety-critical segments are flagged for mandatory human review. AI output is a starting point, not a finished product.

The organizations that will benefit most from AI in regulated translation are those that invest in the governance infrastructure first, and the technology second.

What This Looks Like in Practice: Three Scenarios

Scenario 1: The Pre-SSCP Authoring Gap

A mid-size Class III device manufacturer approaches SSCP preparation with six months until their MDR deadline. Their regulatory team is experienced, but SSCP authoring in plain language for a lay audience is new territory. They commission translation of their existing clinical summary into 12 EU languages, assuming the authoring is already done.

The notified body review identifies multiple issues: sections written at a technical level inappropriate for lay readers, promotional language that is inconsistent with SSCP guidance, and terminology that diverges from the device's own labeling. The document requires substantial revision before it can be validated — and each revision cycle triggers re-translation across all 12 languages.

The scenario is avoidable. SSCP authoring and translation are not sequential steps — they are integrated disciplines that need to be planned together. A plain language review at the authoring stage, before translation begins, eliminates the most costly revision cycles. This is a foundational part of our medical device translation methodology.

Scenario 2: The PSUR Update Cascade

A Class IIb manufacturer with devices marketed across 18 EU Member States enters their second PSUR cycle under MDR. Their PMS team generates updated clinical evaluation data that requires revisions to the SSCP and IFU.

Without integrated version control and translation workflow management, the update process takes longer than the compliance team anticipated. Some language versions are revised; others are not flagged for update. A Competent Authority market surveillance review requests documentation confirmation that all national language versions reflect the current IFU — and the compliance team cannot immediately confirm.

The operational lesson: PSUR cycles are predictable. Translation update workflows should be built into the compliance calendar as standard recurring events, not reactive briefs. Language Intelligence works with manufacturers to establish update triggers and workflow protocols that absorb the annual PSUR cycle without operational disruption.

Scenario 3: Field Safety Notice Speed

A manufacturer issues a Field Safety Corrective Action (FSCA) following a post-market signal. A Field Safety Notice (FSN) must be issued to healthcare professionals and end users across multiple Member States within a defined window. Each national market requires the FSN in its national language or languages, in the correct format, at the correct reading level.

This is where language governance pays its most visible dividend. A manufacturer with pre-established controlled glossaries, qualified reviewers by language, and documented workflows for urgent safety communications can mobilize FSN translation across 10–15 languages within hours. A manufacturer without that infrastructure is improvising under regulatory time pressure — a situation where errors are more likely and consequences are direct.

Speed in safety communications is not just operational — it is a patient safety obligation.

Building a Lifecycle Language Strategy

The MDR and IVDR compliance environment rewards manufacturers who treat language as a regulated asset — planned, governed, auditable, and continuously maintained. Here is what that looks like as a structured discipline.

Terminology governance. A controlled multilingual glossary is the foundation. Device-specific terminology, regulatory terms, IFU language conventions, and safety terminology should be locked at the outset and maintained across all document types and all revision cycles. Without controlled terminology, consistency across languages and across time is a matter of luck.

Integrated update workflows. Language workflows should be embedded in your regulatory calendar, not triggered ad hoc. PSUR cycles, certificate renewals, post-market clinical follow-up outcomes, and labeling updates all have defined schedules. Language planning should map to those schedules.

Tiered review standards. Not all content requires the same level of human review. A structured tiered approach — AI-assisted with expert review for standard content, full expert authoring for SSCP/SSP and safety communications, and mandatory specialist review for numerically and clinically critical language — delivers efficiency without compromising safety.

Audit readiness. Every translation project should produce documentation: source and target versions, translators and reviewers, glossary version used, review decisions made. In a regulated environment, the process is part of the product. Language Intelligence operates under an ISO 9001:2015-certified Quality Management System that provides exactly this auditability across every project.

Economic operator alignment. If your supply chain includes Authorized Representatives, importers, or distributors who interact with language — either verifying existing translations or introducing new ones — they need to operate within your language governance framework, not independently of it.

Language Compliance Is Not a Cost Center — It Is a Risk Management Function

For quality and compliance teams, the case for investing in structured language governance is not primarily about cost reduction. It is about risk reduction — and about the operational resilience that comes from not discovering language gaps during a notified body audit or a Competent Authority review.

The regulatory environment under MDR and IVDR is more rigorous, more public, and more continuous than what it replaced. Language is the mechanism through which regulatory transparency becomes real. Poorly managed translation introduces risk at every stage of the product lifecycle. Strategically managed language governance turns a complex compliance obligation into a reproducible, auditable, and scalable process.

At Language Intelligence, we work with quality and compliance teams to build that capability: ISO 9001:2015-certified quality management, controlled terminology systems, AI-assisted efficiency within expert-governed workflows, and deep experience across the full range of MDR and IVDR document types.

If you are evaluating your current language program against what MDR and IVDR actually require — or preparing for an update cycle, a new market entry, or a notified body review — we welcome the conversation.

Language Intelligence provides specialist medical device translation for manufacturers placing devices on the EU market. Learn more at https://www.languageintelligence.com/life-sciences-translation-services.